NCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
Clinical Trials
9 trialsNCT03082534 2026-01-28
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT00833261 2020-08-21
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00524017 2020-03-12
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01445405 2019-12-17
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00462735 2018-03-13
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01435252 2017-11-06
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
University of Zurich
Phase 2 Completed
NCT00508664 2015-06-02
DeLOS II
University of Leipzig
Phase 2 Completed
NCT00169247 2011-06-27
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Completed